Business Context and Reporting Period
This Form 8-K is a current report filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on April 16, 2021. The filing discloses two primary events: an amendment to a material definitive agreement regarding a patent license and the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial-related disclosure involves a specific equity transaction:
- Equity Conversion: An amendment to a license agreement caused the conversion of 500 shares of Series M Convertible Preferred Stock into 625,000 restricted shares of common stock.
- Effective Date: The conversion is effective as of January 5, 2021.
Material Changes
The following material changes were reported:
- Agreement Amendment: On April 12, 2021, the Company amended its exclusive patent license agreement with Silo Pharma Inc. The amendment modified license fees and triggered the aforementioned stock conversion.
- Board Appointment: Effective April 12, 2021, Kyle Wool was appointed as a member of the Board of Directors and the Compensation Committee.
Guidance, Outlook, and Risks
Management Commentary: The Company stated that Mr. Wool is well-qualified to serve as a director due to his extensive experience in banking and wealth management, including prior roles at Morgan Stanley and Oppenheimer and Co.
Risks and Contingencies: The filing notes that Mr. Wool was involved in an arbitration proceeding with FINRA in 2009, which was settled in 2011. No other specific risks, contingencies, or forward-looking guidance regarding financial performance were disclosed in this report.
Investor Verification Checklist
- Verify the exact terms of the license fee amendments in the attached Exhibit 10.2.
- Confirm the impact of the 625,000 new restricted shares on total outstanding common stock and potential dilution.
- Review the details of the 2009 FINRA arbitration settlement involving the new director, Kyle Wool.
- Check subsequent filings for any financial impact resulting from the license fee adjustments.